Advertisement

Topics

Teprotumumab, Canagliflozin, and Kevin Pho Top AACE Agenda

11:38 EDT 16 Apr 2019 | Medscape

Graves' ophthalmopathy, type 2 diabetes treatment, social media matters, and much more to be featured at Los Angeles conference.
Medscape Medical News

Original Article: Teprotumumab, Canagliflozin, and Kevin Pho Top AACE Agenda

NEXT ARTICLE

More From BioPortfolio on "Teprotumumab, Canagliflozin, and Kevin Pho Top AACE Agenda"

Advertisement
Quick Search
Advertisement
Advertisement